...
首页> 外文期刊>Bioorganic and medicinal chemistry >Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study
【24h】

Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study

机译:发现Indolin-2-One衍生物作为有效的PAK4抑制剂:结构 - 活性关系分析,生物学评估和分子对接研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Utilizing a pharmacophore hybridization approach, a novel series of substituted indolin-2-one derivatives were designed, synthesized and evaluated for their in vitro biological activities against p21-activated kinase 4. Compounds 11b, 12d and 12g exhibited the most potent inhibitory activity against PAK4 (IC50 = 22 nM, 16 nM and 27 nM, respectively). Among them, compound 12g showed the highest antiproliferative activity against A549 cells (IC50 = 0.83 mu M). Apoptosis analysis in A549 cells suggested that compound 12g delayed cell cycle progression by arresting cells in the G2/M phase of the cell cycle, retarding cell growth. Further investigation demonstrated that compound 12g strongly inhibited migration and invasion of A549 cells. Western blot analysis indicated that compound 12g potently inhibited the PAK4/ LIMK1/cofilin signalling pathways. Finally, the binding mode between compound 12g with PAK4 was proposed by molecular docking. A preliminary ADME profile of the compound 12g was also drawn on the basis of QikProp predictions. (C) 2017 Elsevier Ltd. All rights reserved.
机译:利用药效杂交方法,设计了一种新型取代的吲哚-2-一衍生物,用于对P21活化激酶的体外生物活性进行设计,合成和评价。化合物11b,12d和12g表现出对pak4的最有效的抑制活性(IC50 = 22nm,16nm和27 nm)。其中,化合物12G显示出对A549细胞的最高抗增殖活性(IC50 =0.83μm)。 A549细胞中的凋亡分析表明,化合物12G通过在细胞周期的G2 / M期的细胞中延迟细胞延迟细胞周期进展,延迟细胞生长。进一步调查表明,化合物12g强烈抑制A549细胞的迁移和侵袭。 Western印迹分析表明,化合物12G效果抑制了PAK4 / LIMK1 / Cofilin信号传导途径。最后,通过分子对接提出了具有PAK4的化合物12g之间的结合模式。还在Qikprop预测的基础上绘制化合物12G的初步Adme概况。 (c)2017 Elsevier Ltd.保留所有权利。

著录项

  • 来源
    《Bioorganic and medicinal chemistry》 |2017年第13期|共12页
  • 作者单位

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

    Shenyang Pharmaceut Univ Key Lab Struct Based Drug Design &

    Discovery Minist Educ Shenyang;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    p21-Activated kinase; PAK4 inhibitor; lndolin-2-one; Structure-activity relationship; Molecular docking;

    机译:P21-活性激酶;PAK4抑制剂;LNDOLIN-2-one;结构 - 活动关系;分子对接;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号